Summary
With the ageing of the population, neurodegenerative diseases will be a huge societal, health and economic problem. There are no effective solutions that can stop the progression of these devastating diseases. At BrainEver we are developing a groundbreaking platform to treat neurodegenerative diseases based on a family of transcription factors called Homeoproteins (HPs). Homeoproteins are endogenous proteins expressed in diverse neuronal types, where they regulate age-dependent mechanisms related to neurodegeneration. When homeoproteins are injected into the central nervous system of animals with disease, neuronal survival and function is restored, halting degeneration. This suggests a huge potential as therapies for neurodegenerative diseases. In this project, we aim to develop and clinically validate a revolutionary therapy using the homeoprotein Engrailed-1, to treat patients with Amyotrophic Lateral Sclerosis (ALS) and Parkinson’s Disease (PD).
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190105256 |
| Start date: | 01-11-2022 |
| End date: | 31-10-2024 |
| Total budget - Public funding: | 5 523 750,00 Euro - 2 500 000,00 Euro |
Cordis data
Original description
With the ageing of the population, neurodegenerative diseases will be a huge societal, health and economic problem. There are no effective solutions that can stop the progression of these devastating diseases. At BrainEver we are developing a groundbreaking platform to treat neurodegenerative diseases based on a family of transcription factors called Homeoproteins (HPs). Homeoproteins are endogenous proteins expressed in diverse neuronal types, where they regulate age-dependent mechanisms related to neurodegeneration. When homeoproteins are injected into the central nervous system of animals with disease, neuronal survival and function is restored, halting degeneration. This suggests a huge potential as therapies for neurodegenerative diseases. In this project, we aim to develop and clinically validate a revolutionary therapy using the homeoprotein Engrailed-1, to treat patients with Amyotrophic Lateral Sclerosis (ALS) and Parkinson’s Disease (PD).Status
SIGNEDCall topic
HORIZON-EIC-2022-ACCELERATOROPEN-01Update Date
09-02-2023
Images
No images available.
Geographical location(s)
